Safety and pharmacodynamics of anti‐CD2 monoclonal antibody treatment in cynomolgus macaques – an experimental study
Authors:
Open Access
- 15 September 2019
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 33 (1) , 98-107
Abstract
Anti‐CD2 treatment provides targeted immunomodulatory properties that have demonstrated clinical usefulness to condition the immune system and to treat transplant rejection. The treatment is species‐specific due to structural CD2 antigen differences between nonhuman primates and humans. Herein, we report the safety profile and efficacy of two modifications of the same anti‐CD2 monoclonal antibody in cynomolgus macaques. Twelve subjects received one i.v. anti‐CD2 (of rat or rhesus type) dose each, range 1–4 mg/kg, and were followed for 1–7 days. Treatment effects were evaluated with flow cytometry on peripheral blood and histopathological evaluation of secondary lymphoid organs. In vitro inhibitory activity on primary MHC disparate mixed lymphocyte reactions (MLRs) was determined. Upon anti‐CD2 treatment, CD4+, CD8+ memory subsets were substantially depleted. Naïve T cells and Tregs were relatively spared and exhibited lower CD2 expression than memory T cells. Early immune reconstitution was noted for naïve cells, while memory counts had not recovered after one week. Both antibodies displayed a concentration‐dependent MLR inhibition. Lymph node examination revealed no significant lymphocyte depletion. None of the animals experienced any significant study drug‐related adverse events. This study outlines the safety and pharmacodynamic profile of primate‐specific anti‐CD2 treatment, relevant for translation of anti‐CD2‐based animal models into clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Early expansion of donor-specific Tregs in tolerant kidney transplant recipientsJCI Insight, 2018
- Safety profile of intravenous and subcutaneous siplizumab, an anti‐CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double‐blind, placebo‐controlled studiesInternational Journal of Dermatology, 2010
- Safety Profile, Pharmacokinetics, and Pharmacodynamics of Siplizumab, A Humanized Anti-CD2 Monoclonal Antibody, in Renal Allograft RecipientsTransplantation Proceedings, 2009
- HLA-Mismatched Renal Transplantation without Maintenance ImmunosuppressionNew England Journal of Medicine, 2008
- The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletionClinical and Experimental Immunology, 2004
- SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLSTransplantation, 1999
- Prevention of rejection with BTI-322 after renal transplantation (results at 9 months)Transplantation Proceedings, 1997
- An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitroInternational Immunology, 1996
- CD2-mediated adhesion facilitates T lymphocyte antigen recognition functionNature, 1989
- T cell activation via CD2 [T, gp50]: the role of accessory cells in activating resting T cells via CD2.The Journal of Immunology, 1986